Symphony IL-6 Reference Range Study
NCT05048888 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2023-08-14
Summary
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing. Symphony IL-6 comprises two components, the Symphony Fluorescence Immunoanalyzer and the Symphony IL-6 Cartridge. Whole blood is added to the cartridge and then up to six cartridges can be inserted into the immunoanalyzer. After 20 minutes a readout and printout are given with a quantitative IL-6 concentration. The used cartridges are fully enclosed and can be easily disposed of in general hospital bio-waste. Given the nature of this device and its portability, there is potential for future deployment as a point-of-care (POC) device.
The objective of this study is to establish a reference range for Symphony IL-6 in a cohort of apparently healthy individuals.
Conditions
Sponsors & Collaborators
-
Bluejay Diagnostics, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-08-31
- Primary Completion
- 2024-03-30
- Completion
- 2024-03-30
Countries
- United States
Study Locations
More Related Trials
-
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
NCT01842386 ·Status: COMPLETED ·Phase: PHASE1
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT06991114 ·Status: RECRUITING ·Phase: PHASE2
-
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
NCT00719680 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Two Formulations of Ixekizumab in Healthy Participants
NCT04259346 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TAK-881 in Healthy Adults
NCT05059977 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency
NCT00004695 ·Status: COMPLETED ·Phase: NA
-
A Study of Ixekizumab in Healthy Participants
NCT03848416 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
NCT03053622 ·Status: COMPLETED ·Phase: PHASE1
-
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
NCT07113743 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
NCT05013034 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Tocilizumab in Adult's Still Disease
NCT01002781 ·Status: UNKNOWN ·Phase: PHASE2
-
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
NCT00072592 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2/3 Study of IGSC, 20% in PIDD
NCT01218438 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
NCT05120830 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
NCT06435845 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I of XKH001Injection in Healthy Adults
NCT05128409 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Injections of LY3074828 in Healthy Participants
NCT03886948 ·Status: COMPLETED ·Phase: PHASE1
-
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
NCT05416307 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
NCT00419341 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
NCT03014674 ·Status: COMPLETED ·Phase: PHASE3
-
Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
NCT03010436 ·Status: UNKNOWN ·Phase: PHASE2
-
Pathogen Specific Immunity in Patients With Sarcoidosis
NCT00217789 ·Status: COMPLETED
-
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
NCT04445038 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
NCT02543918 ·Status: COMPLETED ·Phase: PHASE1